Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belumosudil - Kadmon Pharmaceuticals

Next Previous
X
Search
Drug Profile

Belumosudil - Kadmon Pharmaceuticals

Alternative Names: Belumosudil mesylate - Kadmon Pharmaceuticals; BN-101; KD-025; KD025 mesylate; ME-3208; REZUROCK; Rholistiq; SAR445761; SLX-2119

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Surface Logix
  • Developer BK Pharmaceuticals; Kadmon Pharmaceuticals; Meiji Seika Pharma; Romeck Pharma; Sanofi
  • Class Acetamides; Amines; Anti-inflammatories; Antifibrotics; Antipsoriatics; Antirheumatics; Hepatoprotectants; Indazoles; Phenyl ethers; Quinazolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Graft-versus-host disease
  • Phase III Lung transplant rejection
  • Phase II Idiopathic pulmonary fibrosis; Systemic scleroderma
  • Preclinical Multiple myeloma
  • No development reported Autoimmune disorders
  • Discontinued Non-alcoholic steatohepatitis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (PO)
  • 17 Jun 2024 Updated adverse event data data from a phase III trial in Graft-versus-host disease, were released by Meiji Seika Pharma
  • 06 Jun 2024 Kadmon completes a phase II extended treatment and follow-up trial for Graft versus host disease in the US (PO, Tablet) (NCT05305989)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top